Gil Gil, MiguelAlba, EmilioGavilá, JoaquínHaba Rodríguez, Juan de laCiruelos, EvaTolosa, PabloCandini, DanieleLlombart Cussac, Antonio2021-07-122021-07-122021-07-01https://hdl.handle.net/2445/179012The use of cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) has proven to be a successful strategy in the treatment of advanced hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-) breast cancer (BC), leading to a strong interest in their possible role in the treatment of early luminal BC. In this review we collect the most relevant and recent information on the use of CDK4/6i for the treatment of early BC in the neoadjuvant and adjuvant settings. Specifically, we evaluate the results of the large phase 3 adjuvant trials recently released, which have yielded apparently divergent results. We also examine the relevance of biomarkers as response predictive factors for CDI4/6i, the combination between radiotherapy and CDK4/6i, and provide a critical discussion on the evidence that we have so far and future directions of the role of these drugs in the treatment of early BC.10 p.application/pdfengCC BY (c) Gil Gil, Miguel et al., 2021http://creativecommons.org/licenses/by/3.0/es/Càncer de mamaTractament adjuvant del càncerBreast cancerAdjuvant treatment of cancerinfo:eu-repo/semantics/article2021-07-09info:eu-repo/semantics/openAccess34087775